Fayez Sarofim & CO Novartis Ag Transaction History

Fayez Sarofim & CO

$38.7 Billion
Q3 2024

A detailed history of Fayez Sarofim & CO transactions in Novartis Ag stock. As of the latest transaction made, Fayez Sarofim & CO holds 40,240 shares of NVS stock, worth $3.96 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

40,240

Previous 39,990 0.63%

Holding current value

$3.96 Million

Previous $4.26 Million 8.72%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$106.13 - $120.89 $26,532 - $30,222	250 Added 0.63%	40,240 $4.63 Million
Q2 2024 Aug 14, 2024	SELL	$92.57 - $107.37 $871,083 - $1.01 Million	-9,410 Reduced 19.05%	39,990 $4.26 Million
Q1 2024 May 14, 2024	SELL	$95.27 - $108.47 $197,685 - $225,075	-2,075 Reduced 4.03%	49,400 $4.78 Million
Q4 2023 Feb 14, 2024	SELL	$92.27 - $101.54 $1.19 Million - $1.31 Million	-12,865 Reduced 20.0%	51,475 $5.2 Million
Q3 2023 Nov 14, 2023	SELL	$94.73 - $105.13 $5.04 Million - $5.59 Million	-53,160 Reduced 45.24%	64,340 $6.55 Million
Q2 2023 Aug 14, 2023	SELL	$92.52 - $104.91 $11 Million - $12.5 Million	-118,745 Reduced 50.26%	117,500 $11.9 Million
Q1 2023 May 11, 2023	SELL	$80.03 - $92.81 $8.83 Million - $10.2 Million	-110,285 Reduced 31.83%	236,245 $21.7 Million
Q4 2022 Feb 13, 2023	SELL	$75.55 - $92.52 $2.37 Million - $2.9 Million	-31,315 Reduced 8.29%	346,530 $31.4 Million
Q3 2022 Nov 14, 2022	SELL	$74.61 - $87.26 $1.98 Million - $2.31 Million	-26,486 Reduced 6.55%	377,845 $28.7 Million
Q2 2022 Aug 12, 2022	SELL	$80.52 - $93.75 $887,733 - $1.03 Million	-11,025 Reduced 2.65%	404,331 $34.2 Million
Q1 2022 May 16, 2022	BUY	$80.11 - $90.62 $332,937 - $376,616	4,156 Added 1.01%	415,356 $36.4 Million
Q4 2021 Feb 11, 2022	BUY	$79.7 - $88.13 $720,966 - $797,223	9,046 Added 2.25%	411,200 $36 Million
Q3 2021 Nov 15, 2021	SELL	$81.78 - $95.14 $990,928 - $1.15 Million	-12,117 Reduced 2.92%	402,154 $32.9 Million
Q2 2021 Aug 13, 2021	SELL	$85.24 - $94.15 $1.1 Million - $1.22 Million	-12,954 Reduced 3.03%	414,271 $37.8 Million
Q1 2021 May 13, 2021	BUY	$83.5 - $98.47 $281,395 - $331,843	3,370 Added 0.8%	427,225 $36.5 Million
Q4 2020 Feb 11, 2021	SELL	$78.07 - $94.43 $132,719 - $160,531	-1,700 Reduced 0.4%	423,855 $40 Million
Q3 2020 Nov 13, 2020	SELL	$82.14 - $91.0 $965,145 - $1.07 Million	-11,750 Reduced 2.69%	425,555 $37 Million
Q2 2020 Aug 11, 2020	BUY	$80.93 - $91.1 $8,093 - $9,110	100 Added 0.02%	437,305 $38.2 Million
Q1 2020 May 12, 2020	SELL	$70.67 - $99.01 $253,917 - $355,742	-3,593 Reduced 0.82%	437,205 $36 Million
Q4 2019 Feb 14, 2020	SELL	$84.35 - $95.37 $604,536 - $683,516	-7,167 Reduced 1.6%	440,798 $41.7 Million
Q3 2019 Nov 13, 2019	SELL	$85.54 - $94.26 $453,362 - $499,578	-5,300 Reduced 1.17%	447,965 $38.9 Million
Q2 2019 Aug 09, 2019	BUY	$75.4 - $92.8 $391,326 - $481,632	5,190 Added 1.16%	453,265 $41.4 Million
Q1 2019 May 14, 2019	SELL	$75.32 - $86.15 $1.81 Million - $2.06 Million	-23,966 Reduced 5.08%	448,075 $43.1 Million
Q4 2018 Feb 13, 2019	SELL	$73.66 - $82.02 $4.41 Million - $4.91 Million	-59,902 Reduced 11.26%	472,041 $40.5 Million
Q3 2018 Nov 14, 2018	SELL	$66.94 - $77.43 $22 Million - $25.4 Million	-328,319 Reduced 38.17%	531,943 $45.8 Million
Q2 2018 Aug 14, 2018	SELL	$64.91 - $73.36 $29.7 Million - $33.6 Million	-457,784 Reduced 34.73%	860,262 $65 Million
Q1 2018 May 10, 2018	SELL	$70.39 - $84.15 $2.32 Million - $2.77 Million	-32,918 Reduced 2.44%	1,318,046 $107 Million
Q4 2017 Feb 13, 2018	SELL	$72.33 - $77.64 $6.46 Million - $6.93 Million	-89,282 Reduced 6.2%	1,350,964 $113 Million
Q3 2017 Nov 08, 2017	BUY	$74.14 - $77.27 $107 Million - $111 Million	1,440,246	1,440,246 $124 Million

Others Institutions Holding NVS

# of Institutions

1,437

Shares Held

131M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $212B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account